0001209191-11-046264.txt : 20110901
0001209191-11-046264.hdr.sgml : 20110901
20110901141555
ACCESSION NUMBER: 0001209191-11-046264
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20110831
FILED AS OF DATE: 20110901
DATE AS OF CHANGE: 20110901
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA
CENTRAL INDEX KEY: 0000875320
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043039129
STATE OF INCORPORATION: MA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 130 WAVERLY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139-4242
BUSINESS PHONE: 6165776000
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kelly Lisa
CENTRAL INDEX KEY: 0001349077
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19319
FILM NUMBER: 111070585
MAIL ADDRESS:
STREET 1: 125 SPRING STREET
CITY: LEXINGTON
STATE: MA
ZIP: 02421
4
1
doc4.xml
FORM 4 SUBMISSION
X0304
4
2011-08-31
0
0000875320
VERTEX PHARMACEUTICALS INC / MA
VRTX
0001349077
Kelly Lisa
C/O VERTEX PHARMACEUTICALS INCORPORATED
130 WAVERLY ST
CAMBRIDGE
MA
02139
0
1
0
0
SVP, Human Resources
Common Stock
2011-08-31
4
M
0
953
18.93
A
39035
D
Common Stock
2011-08-31
4
S
0
1527
45.63
D
37508
D
Common Stock
2011-08-31
4
S
0
800
46.17
D
36708
D
Common Stock
1520
I
401(k)
Stock Options
18.93
2011-08-31
4
M
0
953
0.00
D
2008-05-15
2018-05-14
Common Stock
953
953
D
Transaction made pursuant to Ms. Kelly-Croswell's company approved trading plan under Rule 10b5-1.
Open market sales reported on this line occurred at a weighted average price of $45.63 (range $45.17 to $45.96).
Ms. Kelly-Croswell undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Open market sales reported on this line occurred at a weighted average price of $46.17 (range $46.00 to $46.44).
Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/07/2008, except that the first quarterly vesting occurred on May 15, 2008.
Valerie L. Andrews, Attorney-In-Fact
2011-09-01